SCHEMBL6940420

SCHEMBL6940420

O=[N+]([O-])c1ccccc1C(O)c1cccnc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.54
CYP1A2 P05177 3/20 0.46
MAPT P10636 2/20 0.46
CYP2C9 P11712 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 2/20 0.44
TSHR P16473 2/20 0.43
CYP17A1 P05093 1/20 0.43
HTT P42858 2/20 0.43
ALDH1A1 P00352 2/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
CFTR P13569 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23458474 0.83 CYP1A2 (0.46) GAASMN1; SMN2CYP1A2MAPTTSHR
SCHEMBL31633570 0.82 CYP1A2 (0.56) CYP1A2MAPTCYP2C9KMT2AL3MBTL1
SCHEMBL5583438 0.82 CYP1A2 (0.56) CYP1A2MAPTCYP2C9KMT2AL3MBTL1
SCHEMBL506668 0.79 CYP1A2 (0.58) CYP1A2KMT2ATSHRALDH1A1
SCHEMBL7116027 0.76 SMN1; SMN2 (0.62) GAASMN1; SMN2MAPTKMT2AL3MBTL1
SCHEMBL9489211 0.75 GAA (0.47) GAACYP1A2MAPTCYP2C9KMT2A
SCHEMBL17064638 0.75 MAPT (0.50) SMN1; SMN2CYP1A2MAPTCYP2C9KMT2A
SCHEMBL17064740 0.75 SMN1; SMN2 (0.49) GAASMN1; SMN2CYP1A2MAPTCYP2C9
SCHEMBL31067609 0.75 SMN1; SMN2 (0.49) GAASMN1; SMN2CYP1A2MAPTCYP2C9
SCHEMBL31067705 0.75 MAPT (0.50) SMN1; SMN2CYP1A2MAPTCYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1342719-A1 Benzodiazepine derivatives useful as CCK-Receptor Antagonists YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-09-10 EP disclosed
EP-0628033-B1 BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS YAMANOUCHI PHARMA CO LTD (JP) 2003-07-23 EP disclosed
WO-2003026664-A1 2-PHENYLAMINO-4- (5-PYRAZOLYLAMINO) -PYRAMIDINE DERIVATIVES AS KINASE INHIBITORS, IN PARTICULAR, SRC KINASE INHIBITORS BAYER CORPORATION (US) 2003-04-03 WO disclosed
US-5962451-A GASTROINTESTINAL DISORDERS; ANTIULCER AGENT; ANTICANCER AGENTS; SIDE-EFFECT REDUCTION FERRING BV (NL) 1999-10-05 US disclosed
US-5688943-A CHOLECYSTOKININ ANTAGONIST; ANTIULCER AGENTS; PSYCHOLOGICAL DRUGS; ANXIOLYTIC AGENTS; CONTROLLING APPETITE YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1997-11-18 US disclosed
WO-1993016999-A1 BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1993-09-02 WO disclosed